Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Showing posts with label federal legislation. Show all posts
Showing posts with label federal legislation. Show all posts
Sunday, September 22, 2013
Eight Question of the Day, September 22, 2013, Will the slow progress of Congress in passing legislation to deal with the compounding pharmacy problem have any impacts on whether some in the House and Senate get reelected? Would the passage of federal compounding legislation help them in getting reelected?
Third Question of the Day, September 22, 2013 In light of the fact very few state boards of pharmacy have started to strictly and swiftly enforce state compounding laws, regulations and rules against compounding pharmacies and pharmacists, why hasn't Congress taken prompt action to give the FDA much needed clearly defined authority over compounding pharmacies and pharmacists that are a danger to the public safety and health?
Tuesday, December 25, 2012
Smooth Sailing For FDA
Volume 90 Issue 52 | p. 35
Issue Date: December 24, 2012
Issue Date: December 24, 2012
Congress made it a top priority this year to pass the FDA Safety &
Innovation Act (S. 3187), a bill that reauthorizes FDA to collect fees from the
pharmaceutical and medical device industries to help accelerate the review of
new drugs and devices. After numerous hearings this year, the bill cleared both
the House of Representatives and Senate in June and was then signed into law by
President Barack Obama.
The legislation allows FDA to collect user fees from industry for five years,
beginning in fiscal 2013. Such fees provide about 60% of FDA’s drug review
budget and 20% of its device center budget. The bill also authorizes, for the
first time, user-fee programs for generic drugs and biosimilars—the generic
equivalents of biologic drugs. In addition, it permanently authorizes two
programs aimed at increasing the safety and effectiveness of drugs and medical
devices for children.
Concerns of drug shortages and the safety of an increasingly globalized drug
supply chain also prompted lawmakers to tack on several regulatory reforms to the FDAuser-fee bill.
Also part of the user-fee law is a provision that criminalizes a host of designer drugs. The law bans virtually all synthetic marijuana
compounds, two stimulants sold as bath salts, and nine hallucinogens called 2C
substances for the two-carbon bridge that links a benzene ring and an amino
group in these compounds.
FDA was on the congressional radar again this fall because of a multistate outbreak of fungal meningitis, linked to a
Massachusetts-based compounding pharmacy that produced injectable steroids.
Lawmakers questioned whether the agency has sufficient oversight of compounding
pharmacies. Such pharmacies typically mix small batches of drugs and are
regulated at the state level, whereas large-scale drug manufacturers are
regulated by FDA.
Lawmakers believe that the pharmacy responsible for the meningitis outbreak,
the New England Compounding Center, was operating as a drug manufacturer under
the guise of a compounding pharmacy.
Hearings related to FDA oversight of compounding pharmacies were held in both
the Senate and House after news of the outbreak. In addition, last month Rep.
Edward J. Markey (D-Mass.) introduced H.R. 6584. The bill would preserve state
regulatory authority for small compounding activities and ensure that pharmacies
operating as drug manufacturers are regulated by FDA.
Earlier this month, House lawmakers sent a letter to the International
Association of Compounding Pharmacies, questioning whether the industry group
has a history of encouraging compounding pharmacies to impede FDA from
evaluating their products.
Wednesday, October 24, 2012
What Markey's Planned Federal Legislation Will Include
Lawmaker commends MA Governor, will introduce
legislation addressing loopholes in federal oversight of compounding
pharmacies
WASHINGTON, D.C. – Congressman Edward J. Markey (D-Mass.), senior member of
the Energy and Commerce Committee, which has jurisdiction over the Food and Drug
Administration (FDA), today released the following statement after Massachusetts
Governor Deval Patrick and state public health officials announced they are
taking steps to address the regulation of compounding pharmacies in the wake of
the meningitis outbreak caused by contaminated drugs from the New England
Compounding Center (NECC). The state announced the preliminary results of its
NECC investigation, which found numerous violations of good sterile compounding
practices and other problems, said that it will begin making periodic
unannounced inspections of compounding pharmacies that prepare sterile
injectable medications; require compounding pharmacies in Massachusetts to
submit annual reports of production, volume and distribution of medications;
require compounding pharmacies to report to the Board of Pharmacies all
interactions with federal regulatory authorities; and form a special commission
to examine best practices and advise the state on what changes should make in
state law to further assure the public’s safety.“It is now clear that the New England Compounding Center violated state law and endangered the health of countless patients. I commend Governor Patrick and state and federal officials for their ongoing investigation and for taking immediate and decisive action to update state practices. This is a deadly serious situation involving highly sensitive drugs and vulnerable patients, demanding the strongest response from state and federal authorities and Congress. The longer these compounding pharmacy loopholes are allowed to remain on the books, the longer patients are at risk. That’s why I plan to introduce legislation addressing the regulatory gaps identified by this investigation and strengthening oversight of compounding pharmacies. I look forward to working with my congressional colleagues in a bipartisan manner to move this legislation forward and ensure the safety of patients in the future.”
Rep. Markey plans to introduce legislation that will:
- Require compounding pharmacies to comply with basic minimum safety standards
- Ban pharmacies from compounding drugs using ingredients that are not approved by the FDA
- Require explicit distinction between compounding pharmacies and drug manufacturers
- Require compounding pharmacies to provide adverse event reports to the FDA
- Require a warning to patients using any compounded pharmaceutical that it has not been approved safe and effective by the FDA
From here
Monday, October 8, 2012
Should New Federal Legislation Similar to the Safe Drug Compound Act of 2007 Giving the FDA Authority to Regulate Compounding Be Enacted in Light of the New England Compounding Center Meningitis Outbreak
The Safe Drug Compounding Act of 2007 was drafted as a Senate bill. Its purpose was to redefine oversight and regulation of the practice of pharmacy compounding by giving power to the FDA to inspect all retail pharmacies that made or dispensed compounded medications and to determine whether or not compounded medications were medically necessary or "essentially copies" of existing FDA-approved medications. The draft bill also would have taken a number of steps to inhibit the distribution of compounded medications beyond state lines by requiring compounding pharmacies to provide detailed documentation on all intrastate orders and asking state pharmacy boards to "discourage the distribution of inordinate amounts of compound drug products in interstate commerce." The bill never passed.
Pharmacists and pharmacy organizations opposed the draft bill, expressing concern that
the Safe Drug Compounding Act of 2007, would restrain the practice of compounding by giving the Food & Drug Administration
authority to regulate compounding. A coalition of nine pharmacy organizations--the American Pharmacists Association, National Community Pharmacists Association, International Academy of Compounding Pharmacists (IACP), American College of Apothecaries, American Society of Consultant Pharmacists, National Alliance of State Pharmacy Associations, Massachusetts Pharmacists Association, North Carolina Association of Pharmacists, and Kansas Pharmacists Association -- drafted a letter to the bill's expected sponsors. insisting that the draft legislation "would negatively impact patient access to necessary compounded
prescription medications and create onerous, new requirements for prescribers
and pharmacists" and urging that this draft legislation not be introduced. The coalition of none pointed out the work
of the U.S. Pharmacopeia, state boards of pharmacy, and the Pharmacy Compounding
Accreditation Board (PCAB) and promised to work with Congress to address
concerns about compounding.
Compounding critics, however, wanted the draft bill to pass, insisted that the act would clarify
several issues that have been unclear since 1997 when the Supreme Court struck
down portions of the FDA Modernization Act (FDAMA) dealing with compounding, and claimed it would help correct the problems and dangers associated with pharmacy compounding. The 2007 legislation was sponsored by Senator Ted Kennedy and co-sponsored by Senators Pat Roberts and Richard Burr. The bill previously failed to become law. Senator Richard Blumenthal (D-Conn.) called for stronger federal oversight of
compounding pharmacies. In a letter to the FDA, Senator Blumenthal states:
“This tragic incident calls for stronger oversight, more exacting standards and stricter enforcement of consumer and patient protections related to compounding pharmacies. I remain particularly concerned that compounding, which is intended for individual patient special needs, may have grown more broadly in some instances, into widespread and multi-state distribution."
To read the entire letter click here. Is federal legislation already in the works? What should the federal legislation cover? What should it not cover? How board should it be?
“This tragic incident calls for stronger oversight, more exacting standards and stricter enforcement of consumer and patient protections related to compounding pharmacies. I remain particularly concerned that compounding, which is intended for individual patient special needs, may have grown more broadly in some instances, into widespread and multi-state distribution."
To read the entire letter click here. Is federal legislation already in the works? What should the federal legislation cover? What should it not cover? How board should it be?
Subscribe to:
Posts (Atom)